Soleno Therapeutics, Inc.
Soleno Therapeutics, Inc. (SLNO) Stock Competitors & Peer Comparison
See (SLNO) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| SLNO | $77.36 | +0.00% | 3.8B | -16.97 | -$4.22 | N/A |
| VRTX | $390.30 | +0.00% | 100.7B | 27.96 | $14.05 | N/A |
| REGN | $565.97 | +0.00% | 60.5B | 14.62 | $39.70 | +0.30% |
| ALNY | $442.73 | +0.00% | 58.8B | -181.01 | -$2.48 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ARGX | $652.43 | +0.00% | 40B | 33.29 | $19.64 | N/A |
| BNTX | $112.70 | +0.00% | 27.3B | -67.98 | -$1.67 | N/A |
| BGNE | $184.71 | +0.49% | 20.2B | -22.55 | -$8.19 | N/A |
| SMMT | $26.45 | +0.00% | 19.8B | -26.43 | -$1.01 | N/A |
| DNA-WT | $0.27 | -2.76% | 18.7B | N/A | N/A | N/A |
Stock Comparison
SLNO vs VRTX Comparison August 2025
SLNO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLNO stands at 3.8B. In comparison, VRTX has a market cap of 100.7B. Regarding current trading prices, SLNO is priced at $77.36, while VRTX trades at $390.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLNO currently has a P/E ratio of -16.97, whereas VRTX's P/E ratio is 27.96. In terms of profitability, SLNO's ROE is -0.74%, compared to VRTX's ROE of +0.22%. Regarding short-term risk, SLNO is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for SLNO.Check VRTX's competition here
SLNO vs REGN Comparison August 2025
SLNO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLNO stands at 3.8B. In comparison, REGN has a market cap of 60.5B. Regarding current trading prices, SLNO is priced at $77.36, while REGN trades at $565.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLNO currently has a P/E ratio of -16.97, whereas REGN's P/E ratio is 14.62. In terms of profitability, SLNO's ROE is -0.74%, compared to REGN's ROE of +0.15%. Regarding short-term risk, SLNO is more volatile compared to REGN. This indicates potentially higher risk in terms of short-term price fluctuations for SLNO.Check REGN's competition here
SLNO vs ALNY Comparison August 2025
SLNO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLNO stands at 3.8B. In comparison, ALNY has a market cap of 58.8B. Regarding current trading prices, SLNO is priced at $77.36, while ALNY trades at $442.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLNO currently has a P/E ratio of -16.97, whereas ALNY's P/E ratio is -181.01. In terms of profitability, SLNO's ROE is -0.74%, compared to ALNY's ROE of -2.74%. Regarding short-term risk, SLNO is more volatile compared to ALNY. This indicates potentially higher risk in terms of short-term price fluctuations for SLNO.Check ALNY's competition here
SLNO vs SGEN Comparison August 2025
SLNO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLNO stands at 3.8B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, SLNO is priced at $77.36, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLNO currently has a P/E ratio of -16.97, whereas SGEN's P/E ratio is -57.19. In terms of profitability, SLNO's ROE is -0.74%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, SLNO is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for SLNO.Check SGEN's competition here
SLNO vs ARGX Comparison August 2025
SLNO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLNO stands at 3.8B. In comparison, ARGX has a market cap of 40B. Regarding current trading prices, SLNO is priced at $77.36, while ARGX trades at $652.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLNO currently has a P/E ratio of -16.97, whereas ARGX's P/E ratio is 33.29. In terms of profitability, SLNO's ROE is -0.74%, compared to ARGX's ROE of +0.26%. Regarding short-term risk, SLNO is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for SLNO.Check ARGX's competition here
SLNO vs BNTX Comparison August 2025
SLNO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLNO stands at 3.8B. In comparison, BNTX has a market cap of 27.3B. Regarding current trading prices, SLNO is priced at $77.36, while BNTX trades at $112.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLNO currently has a P/E ratio of -16.97, whereas BNTX's P/E ratio is -67.98. In terms of profitability, SLNO's ROE is -0.74%, compared to BNTX's ROE of -0.04%. Regarding short-term risk, SLNO is more volatile compared to BNTX. This indicates potentially higher risk in terms of short-term price fluctuations for SLNO.Check BNTX's competition here
SLNO vs BGNE Comparison August 2025
SLNO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLNO stands at 3.8B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, SLNO is priced at $77.36, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLNO currently has a P/E ratio of -16.97, whereas BGNE's P/E ratio is -22.55. In terms of profitability, SLNO's ROE is -0.74%, compared to BGNE's ROE of -0.12%. Regarding short-term risk, SLNO is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for SLNO.Check BGNE's competition here
SLNO vs SMMT Comparison August 2025
SLNO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLNO stands at 3.8B. In comparison, SMMT has a market cap of 19.8B. Regarding current trading prices, SLNO is priced at $77.36, while SMMT trades at $26.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLNO currently has a P/E ratio of -16.97, whereas SMMT's P/E ratio is -26.43. In terms of profitability, SLNO's ROE is -0.74%, compared to SMMT's ROE of -2.09%. Regarding short-term risk, SLNO is more volatile compared to SMMT. This indicates potentially higher risk in terms of short-term price fluctuations for SLNO.Check SMMT's competition here
SLNO vs DNA-WT Comparison August 2025
SLNO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLNO stands at 3.8B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, SLNO is priced at $77.36, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLNO currently has a P/E ratio of -16.97, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, SLNO's ROE is -0.74%, compared to DNA-WT's ROE of -0.45%. Regarding short-term risk, SLNO is less volatile compared to DNA-WT. This indicates potentially lower risk in terms of short-term price fluctuations for SLNO.Check DNA-WT's competition here
SLNO vs INCY Comparison August 2025
SLNO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLNO stands at 3.8B. In comparison, INCY has a market cap of 17B. Regarding current trading prices, SLNO is priced at $77.36, while INCY trades at $86.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLNO currently has a P/E ratio of -16.97, whereas INCY's P/E ratio is 20.55. In terms of profitability, SLNO's ROE is -0.74%, compared to INCY's ROE of +0.34%. Regarding short-term risk, SLNO is more volatile compared to INCY. This indicates potentially higher risk in terms of short-term price fluctuations for SLNO.Check INCY's competition here
SLNO vs RPRX Comparison August 2025
SLNO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLNO stands at 3.8B. In comparison, RPRX has a market cap of 15.7B. Regarding current trading prices, SLNO is priced at $77.36, while RPRX trades at $36.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLNO currently has a P/E ratio of -16.97, whereas RPRX's P/E ratio is 15.87. In terms of profitability, SLNO's ROE is -0.74%, compared to RPRX's ROE of +0.15%. Regarding short-term risk, SLNO is more volatile compared to RPRX. This indicates potentially higher risk in terms of short-term price fluctuations for SLNO.Check RPRX's competition here
SLNO vs GMAB Comparison August 2025
SLNO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLNO stands at 3.8B. In comparison, GMAB has a market cap of 14.7B. Regarding current trading prices, SLNO is priced at $77.36, while GMAB trades at $22.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLNO currently has a P/E ratio of -16.97, whereas GMAB's P/E ratio is 12.08. In terms of profitability, SLNO's ROE is -0.74%, compared to GMAB's ROE of +0.26%. Regarding short-term risk, SLNO is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for SLNO.Check GMAB's competition here
SLNO vs UTHR Comparison August 2025
SLNO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLNO stands at 3.8B. In comparison, UTHR has a market cap of 14.2B. Regarding current trading prices, SLNO is priced at $77.36, while UTHR trades at $312.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLNO currently has a P/E ratio of -16.97, whereas UTHR's P/E ratio is 12.22. In terms of profitability, SLNO's ROE is -0.74%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, SLNO is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for SLNO.Check UTHR's competition here
SLNO vs KRTX Comparison August 2025
SLNO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLNO stands at 3.8B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, SLNO is priced at $77.36, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLNO currently has a P/E ratio of -16.97, whereas KRTX's P/E ratio is -28.09. In terms of profitability, SLNO's ROE is -0.74%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, SLNO is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for SLNO.Check KRTX's competition here
SLNO vs ASND Comparison August 2025
SLNO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLNO stands at 3.8B. In comparison, ASND has a market cap of 12B. Regarding current trading prices, SLNO is priced at $77.36, while ASND trades at $192.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLNO currently has a P/E ratio of -16.97, whereas ASND's P/E ratio is -37.63. In terms of profitability, SLNO's ROE is -0.74%, compared to ASND's ROE of +1.91%. Regarding short-term risk, SLNO is more volatile compared to ASND. This indicates potentially higher risk in terms of short-term price fluctuations for SLNO.Check ASND's competition here
SLNO vs BMRN Comparison August 2025
SLNO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLNO stands at 3.8B. In comparison, BMRN has a market cap of 11B. Regarding current trading prices, SLNO is priced at $77.36, while BMRN trades at $58.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLNO currently has a P/E ratio of -16.97, whereas BMRN's P/E ratio is 16.97. In terms of profitability, SLNO's ROE is -0.74%, compared to BMRN's ROE of +0.11%. Regarding short-term risk, SLNO is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for SLNO.Check BMRN's competition here
SLNO vs MRNA Comparison August 2025
SLNO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLNO stands at 3.8B. In comparison, MRNA has a market cap of 10.9B. Regarding current trading prices, SLNO is priced at $77.36, while MRNA trades at $26.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLNO currently has a P/E ratio of -16.97, whereas MRNA's P/E ratio is -3.73. In terms of profitability, SLNO's ROE is -0.74%, compared to MRNA's ROE of -0.27%. Regarding short-term risk, SLNO is more volatile compared to MRNA. This indicates potentially higher risk in terms of short-term price fluctuations for SLNO.Check MRNA's competition here
SLNO vs EXEL Comparison August 2025
SLNO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLNO stands at 3.8B. In comparison, EXEL has a market cap of 10.3B. Regarding current trading prices, SLNO is priced at $77.36, while EXEL trades at $38.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLNO currently has a P/E ratio of -16.97, whereas EXEL's P/E ratio is 18.42. In terms of profitability, SLNO's ROE is -0.74%, compared to EXEL's ROE of +0.28%. Regarding short-term risk, SLNO is more volatile compared to EXEL. This indicates potentially higher risk in terms of short-term price fluctuations for SLNO.Check EXEL's competition here
SLNO vs BBIO Comparison August 2025
SLNO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLNO stands at 3.8B. In comparison, BBIO has a market cap of 9.8B. Regarding current trading prices, SLNO is priced at $77.36, while BBIO trades at $51.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLNO currently has a P/E ratio of -16.97, whereas BBIO's P/E ratio is -12.43. In terms of profitability, SLNO's ROE is -0.74%, compared to BBIO's ROE of +0.51%. Regarding short-term risk, SLNO is more volatile compared to BBIO. This indicates potentially higher risk in terms of short-term price fluctuations for SLNO.Check BBIO's competition here
SLNO vs RXDX Comparison August 2025
SLNO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLNO stands at 3.8B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, SLNO is priced at $77.36, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLNO currently has a P/E ratio of -16.97, whereas RXDX's P/E ratio is -56.47. In terms of profitability, SLNO's ROE is -0.74%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, SLNO is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for SLNO.Check RXDX's competition here
SLNO vs VRNA Comparison August 2025
SLNO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLNO stands at 3.8B. In comparison, VRNA has a market cap of 8.9B. Regarding current trading prices, SLNO is priced at $77.36, while VRNA trades at $105.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLNO currently has a P/E ratio of -16.97, whereas VRNA's P/E ratio is -101.22. In terms of profitability, SLNO's ROE is -0.74%, compared to VRNA's ROE of -0.90%. Regarding short-term risk, SLNO is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for SLNO.Check VRNA's competition here
SLNO vs IMGN Comparison August 2025
SLNO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLNO stands at 3.8B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, SLNO is priced at $77.36, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLNO currently has a P/E ratio of -16.97, whereas IMGN's P/E ratio is -111.55. In terms of profitability, SLNO's ROE is -0.74%, compared to IMGN's ROE of -1.43%. Regarding short-term risk, SLNO is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for SLNO.Check IMGN's competition here
SLNO vs TECH Comparison August 2025
SLNO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLNO stands at 3.8B. In comparison, TECH has a market cap of 8.4B. Regarding current trading prices, SLNO is priced at $77.36, while TECH trades at $53.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLNO currently has a P/E ratio of -16.97, whereas TECH's P/E ratio is 116.52. In terms of profitability, SLNO's ROE is -0.74%, compared to TECH's ROE of +0.06%. Regarding short-term risk, SLNO is more volatile compared to TECH. This indicates potentially higher risk in terms of short-term price fluctuations for SLNO.Check TECH's competition here
SLNO vs BPMC Comparison August 2025
SLNO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLNO stands at 3.8B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, SLNO is priced at $77.36, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLNO currently has a P/E ratio of -16.97, whereas BPMC's P/E ratio is -51.58. In terms of profitability, SLNO's ROE is -0.74%, compared to BPMC's ROE of -0.49%. Regarding short-term risk, SLNO is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for SLNO.Check BPMC's competition here
SLNO vs MDGL Comparison August 2025
SLNO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLNO stands at 3.8B. In comparison, MDGL has a market cap of 8.2B. Regarding current trading prices, SLNO is priced at $77.36, while MDGL trades at $371.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLNO currently has a P/E ratio of -16.97, whereas MDGL's P/E ratio is -29.21. In terms of profitability, SLNO's ROE is -0.74%, compared to MDGL's ROE of -0.38%. Regarding short-term risk, SLNO is more volatile compared to MDGL. This indicates potentially higher risk in terms of short-term price fluctuations for SLNO.Check MDGL's competition here
SLNO vs CERE Comparison August 2025
SLNO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLNO stands at 3.8B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, SLNO is priced at $77.36, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLNO currently has a P/E ratio of -16.97, whereas CERE's P/E ratio is -16.47. In terms of profitability, SLNO's ROE is -0.74%, compared to CERE's ROE of -0.72%. Regarding short-term risk, SLNO is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for SLNO.Check CERE's competition here
SLNO vs ROIV Comparison August 2025
SLNO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLNO stands at 3.8B. In comparison, ROIV has a market cap of 8.1B. Regarding current trading prices, SLNO is priced at $77.36, while ROIV trades at $11.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLNO currently has a P/E ratio of -16.97, whereas ROIV's P/E ratio is -10.87. In terms of profitability, SLNO's ROE is -0.74%, compared to ROIV's ROE of -0.03%. Regarding short-term risk, SLNO is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for SLNO.Check ROIV's competition here
SLNO vs HALO Comparison August 2025
SLNO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLNO stands at 3.8B. In comparison, HALO has a market cap of 7.9B. Regarding current trading prices, SLNO is priced at $77.36, while HALO trades at $65.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLNO currently has a P/E ratio of -16.97, whereas HALO's P/E ratio is 15.39. In terms of profitability, SLNO's ROE is -0.74%, compared to HALO's ROE of +1.37%. Regarding short-term risk, SLNO is more volatile compared to HALO. This indicates potentially higher risk in terms of short-term price fluctuations for SLNO.Check HALO's competition here
SLNO vs ROIVW Comparison August 2025
SLNO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLNO stands at 3.8B. In comparison, ROIVW has a market cap of 7.8B. Regarding current trading prices, SLNO is priced at $77.36, while ROIVW trades at $2.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLNO currently has a P/E ratio of -16.97, whereas ROIVW's P/E ratio is -0.67. In terms of profitability, SLNO's ROE is -0.74%, compared to ROIVW's ROE of -0.03%. Regarding short-term risk, SLNO is less volatile compared to ROIVW. This indicates potentially lower risk in terms of short-term price fluctuations for SLNO.Check ROIVW's competition here
SLNO vs CORT Comparison August 2025
SLNO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLNO stands at 3.8B. In comparison, CORT has a market cap of 7.6B. Regarding current trading prices, SLNO is priced at $77.36, while CORT trades at $72.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLNO currently has a P/E ratio of -16.97, whereas CORT's P/E ratio is 64.06. In terms of profitability, SLNO's ROE is -0.74%, compared to CORT's ROE of +0.20%. Regarding short-term risk, SLNO is more volatile compared to CORT. This indicates potentially higher risk in terms of short-term price fluctuations for SLNO.Check CORT's competition here
SLNO vs JAZZ Comparison August 2025
SLNO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLNO stands at 3.8B. In comparison, JAZZ has a market cap of 7.1B. Regarding current trading prices, SLNO is priced at $77.36, while JAZZ trades at $116.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLNO currently has a P/E ratio of -16.97, whereas JAZZ's P/E ratio is -16.87. In terms of profitability, SLNO's ROE is -0.74%, compared to JAZZ's ROE of -0.10%. Regarding short-term risk, SLNO is more volatile compared to JAZZ. This indicates potentially higher risk in terms of short-term price fluctuations for SLNO.Check JAZZ's competition here
SLNO vs IONS Comparison August 2025
SLNO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLNO stands at 3.8B. In comparison, IONS has a market cap of 7B. Regarding current trading prices, SLNO is priced at $77.36, while IONS trades at $42.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLNO currently has a P/E ratio of -16.97, whereas IONS's P/E ratio is -24.87. In terms of profitability, SLNO's ROE is -0.74%, compared to IONS's ROE of -0.45%. Regarding short-term risk, SLNO is more volatile compared to IONS. This indicates potentially higher risk in terms of short-term price fluctuations for SLNO.Check IONS's competition here
SLNO vs RVMD Comparison August 2025
SLNO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLNO stands at 3.8B. In comparison, RVMD has a market cap of 6.8B. Regarding current trading prices, SLNO is priced at $77.36, while RVMD trades at $36.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLNO currently has a P/E ratio of -16.97, whereas RVMD's P/E ratio is -8.04. In terms of profitability, SLNO's ROE is -0.74%, compared to RVMD's ROE of -0.39%. Regarding short-term risk, SLNO is more volatile compared to RVMD. This indicates potentially higher risk in terms of short-term price fluctuations for SLNO.Check RVMD's competition here
SLNO vs RETA Comparison August 2025
SLNO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLNO stands at 3.8B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, SLNO is priced at $77.36, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLNO currently has a P/E ratio of -16.97, whereas RETA's P/E ratio is -66.29. In terms of profitability, SLNO's ROE is -0.74%, compared to RETA's ROE of +0.47%. Regarding short-term risk, SLNO is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for SLNO.Check RETA's competition here
SLNO vs RYTM Comparison August 2025
SLNO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLNO stands at 3.8B. In comparison, RYTM has a market cap of 6.5B. Regarding current trading prices, SLNO is priced at $77.36, while RYTM trades at $96.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLNO currently has a P/E ratio of -16.97, whereas RYTM's P/E ratio is -32.43. In terms of profitability, SLNO's ROE is -0.74%, compared to RYTM's ROE of -1.55%. Regarding short-term risk, SLNO is more volatile compared to RYTM. This indicates potentially higher risk in terms of short-term price fluctuations for SLNO.Check RYTM's competition here
SLNO vs RNA Comparison August 2025
SLNO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLNO stands at 3.8B. In comparison, RNA has a market cap of 6B. Regarding current trading prices, SLNO is priced at $77.36, while RNA trades at $46.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLNO currently has a P/E ratio of -16.97, whereas RNA's P/E ratio is -13.05. In terms of profitability, SLNO's ROE is -0.74%, compared to RNA's ROE of -0.33%. Regarding short-term risk, SLNO is more volatile compared to RNA. This indicates potentially higher risk in terms of short-term price fluctuations for SLNO.Check RNA's competition here
SLNO vs ABCM Comparison August 2025
SLNO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLNO stands at 3.8B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, SLNO is priced at $77.36, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLNO currently has a P/E ratio of -16.97, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, SLNO's ROE is -0.74%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, SLNO is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for SLNO.Check ABCM's competition here
SLNO vs ISEE Comparison August 2025
SLNO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLNO stands at 3.8B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, SLNO is priced at $77.36, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLNO currently has a P/E ratio of -16.97, whereas ISEE's P/E ratio is -22.44. In terms of profitability, SLNO's ROE is -0.74%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, SLNO is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for SLNO.Check ISEE's competition here
SLNO vs NUVL Comparison August 2025
SLNO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLNO stands at 3.8B. In comparison, NUVL has a market cap of 5.5B. Regarding current trading prices, SLNO is priced at $77.36, while NUVL trades at $76.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLNO currently has a P/E ratio of -16.97, whereas NUVL's P/E ratio is -15.46. In terms of profitability, SLNO's ROE is -0.74%, compared to NUVL's ROE of -0.33%. Regarding short-term risk, SLNO is more volatile compared to NUVL. This indicates potentially higher risk in terms of short-term price fluctuations for SLNO.Check NUVL's competition here
SLNO vs AXSM Comparison August 2025
SLNO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLNO stands at 3.8B. In comparison, AXSM has a market cap of 5.4B. Regarding current trading prices, SLNO is priced at $77.36, while AXSM trades at $108.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLNO currently has a P/E ratio of -16.97, whereas AXSM's P/E ratio is -21.58. In terms of profitability, SLNO's ROE is -0.74%, compared to AXSM's ROE of -3.58%. Regarding short-term risk, SLNO is more volatile compared to AXSM. This indicates potentially higher risk in terms of short-term price fluctuations for SLNO.Check AXSM's competition here
SLNO vs CRSP Comparison August 2025
SLNO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLNO stands at 3.8B. In comparison, CRSP has a market cap of 5.4B. Regarding current trading prices, SLNO is priced at $77.36, while CRSP trades at $58.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLNO currently has a P/E ratio of -16.97, whereas CRSP's P/E ratio is -11.06. In terms of profitability, SLNO's ROE is -0.74%, compared to CRSP's ROE of -0.25%. Regarding short-term risk, SLNO is less volatile compared to CRSP. This indicates potentially lower risk in terms of short-term price fluctuations for SLNO.Check CRSP's competition here
SLNO vs ABVX Comparison August 2025
SLNO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLNO stands at 3.8B. In comparison, ABVX has a market cap of 5.3B. Regarding current trading prices, SLNO is priced at $77.36, while ABVX trades at $69.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLNO currently has a P/E ratio of -16.97, whereas ABVX's P/E ratio is -20.60. In terms of profitability, SLNO's ROE is -0.74%, compared to ABVX's ROE of -1.06%. Regarding short-term risk, SLNO is more volatile compared to ABVX. This indicates potentially higher risk in terms of short-term price fluctuations for SLNO.Check ABVX's competition here
SLNO vs MRUS Comparison August 2025
SLNO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLNO stands at 3.8B. In comparison, MRUS has a market cap of 5.1B. Regarding current trading prices, SLNO is priced at $77.36, while MRUS trades at $66.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLNO currently has a P/E ratio of -16.97, whereas MRUS's P/E ratio is -12.05. In terms of profitability, SLNO's ROE is -0.74%, compared to MRUS's ROE of -0.55%. Regarding short-term risk, SLNO is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for SLNO.Check MRUS's competition here
SLNO vs ALKS Comparison August 2025
SLNO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLNO stands at 3.8B. In comparison, ALKS has a market cap of 4.8B. Regarding current trading prices, SLNO is priced at $77.36, while ALKS trades at $28.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLNO currently has a P/E ratio of -16.97, whereas ALKS's P/E ratio is 14.03. In terms of profitability, SLNO's ROE is -0.74%, compared to ALKS's ROE of +0.24%. Regarding short-term risk, SLNO is more volatile compared to ALKS. This indicates potentially higher risk in terms of short-term price fluctuations for SLNO.Check ALKS's competition here
SLNO vs CYTK Comparison August 2025
SLNO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLNO stands at 3.8B. In comparison, CYTK has a market cap of 4.6B. Regarding current trading prices, SLNO is priced at $77.36, while CYTK trades at $38.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLNO currently has a P/E ratio of -16.97, whereas CYTK's P/E ratio is -7.55. In terms of profitability, SLNO's ROE is -0.74%, compared to CYTK's ROE of +3.09%. Regarding short-term risk, SLNO is less volatile compared to CYTK. This indicates potentially lower risk in terms of short-term price fluctuations for SLNO.Check CYTK's competition here
SLNO vs VKTX Comparison August 2025
SLNO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLNO stands at 3.8B. In comparison, VKTX has a market cap of 4.5B. Regarding current trading prices, SLNO is priced at $77.36, while VKTX trades at $40.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLNO currently has a P/E ratio of -16.97, whereas VKTX's P/E ratio is -25.99. In terms of profitability, SLNO's ROE is -0.74%, compared to VKTX's ROE of -0.20%. Regarding short-term risk, SLNO is more volatile compared to VKTX. This indicates potentially higher risk in terms of short-term price fluctuations for SLNO.Check VKTX's competition here
SLNO vs ALPN Comparison August 2025
SLNO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLNO stands at 3.8B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, SLNO is priced at $77.36, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLNO currently has a P/E ratio of -16.97, whereas ALPN's P/E ratio is -101.52. In terms of profitability, SLNO's ROE is -0.74%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, SLNO is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for SLNO.Check ALPN's competition here
SLNO vs TGTX Comparison August 2025
SLNO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLNO stands at 3.8B. In comparison, TGTX has a market cap of 4.5B. Regarding current trading prices, SLNO is priced at $77.36, while TGTX trades at $27.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLNO currently has a P/E ratio of -16.97, whereas TGTX's P/E ratio is 73.89. In terms of profitability, SLNO's ROE is -0.74%, compared to TGTX's ROE of +0.29%. Regarding short-term risk, SLNO is more volatile compared to TGTX. This indicates potentially higher risk in terms of short-term price fluctuations for SLNO.Check TGTX's competition here
SLNO vs KRYS Comparison August 2025
SLNO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLNO stands at 3.8B. In comparison, KRYS has a market cap of 4.3B. Regarding current trading prices, SLNO is priced at $77.36, while KRYS trades at $150.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLNO currently has a P/E ratio of -16.97, whereas KRYS's P/E ratio is 30.60. In terms of profitability, SLNO's ROE is -0.74%, compared to KRYS's ROE of +0.15%. Regarding short-term risk, SLNO is more volatile compared to KRYS. This indicates potentially higher risk in terms of short-term price fluctuations for SLNO.Check KRYS's competition here
SLNO vs ACAD Comparison August 2025
SLNO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLNO stands at 3.8B. In comparison, ACAD has a market cap of 4.3B. Regarding current trading prices, SLNO is priced at $77.36, while ACAD trades at $24.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLNO currently has a P/E ratio of -16.97, whereas ACAD's P/E ratio is 19.05. In terms of profitability, SLNO's ROE is -0.74%, compared to ACAD's ROE of +0.31%. Regarding short-term risk, SLNO is more volatile compared to ACAD. This indicates potentially higher risk in terms of short-term price fluctuations for SLNO.Check ACAD's competition here
SLNO vs PCVX Comparison August 2025
SLNO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLNO stands at 3.8B. In comparison, PCVX has a market cap of 4.2B. Regarding current trading prices, SLNO is priced at $77.36, while PCVX trades at $31.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLNO currently has a P/E ratio of -16.97, whereas PCVX's P/E ratio is -7.96. In terms of profitability, SLNO's ROE is -0.74%, compared to PCVX's ROE of -0.17%. Regarding short-term risk, SLNO is more volatile compared to PCVX. This indicates potentially higher risk in terms of short-term price fluctuations for SLNO.Check PCVX's competition here
SLNO vs OPT Comparison August 2025
SLNO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLNO stands at 3.8B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, SLNO is priced at $77.36, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLNO currently has a P/E ratio of -16.97, whereas OPT's P/E ratio is -1.52. In terms of profitability, SLNO's ROE is -0.74%, compared to OPT's ROE of +2.60%. Regarding short-term risk, SLNO is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for SLNO.Check OPT's competition here
SLNO vs AAPG Comparison August 2025
SLNO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLNO stands at 3.8B. In comparison, AAPG has a market cap of 4.1B. Regarding current trading prices, SLNO is priced at $77.36, while AAPG trades at $42.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLNO currently has a P/E ratio of -16.97, whereas AAPG's P/E ratio is -60.54. In terms of profitability, SLNO's ROE is -0.74%, compared to AAPG's ROE of -2.50%. Regarding short-term risk, SLNO is more volatile compared to AAPG. This indicates potentially higher risk in terms of short-term price fluctuations for SLNO.Check AAPG's competition here
SLNO vs MRTX Comparison August 2025
SLNO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLNO stands at 3.8B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, SLNO is priced at $77.36, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLNO currently has a P/E ratio of -16.97, whereas MRTX's P/E ratio is -4.82. In terms of profitability, SLNO's ROE is -0.74%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, SLNO is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for SLNO.Check MRTX's competition here
SLNO vs ACLX Comparison August 2025
SLNO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLNO stands at 3.8B. In comparison, ACLX has a market cap of 4.1B. Regarding current trading prices, SLNO is priced at $77.36, while ACLX trades at $71.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLNO currently has a P/E ratio of -16.97, whereas ACLX's P/E ratio is -21.67. In terms of profitability, SLNO's ROE is -0.74%, compared to ACLX's ROE of -0.43%. Regarding short-term risk, SLNO is less volatile compared to ACLX. This indicates potentially lower risk in terms of short-term price fluctuations for SLNO.Check ACLX's competition here
SLNO vs ADMA Comparison August 2025
SLNO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLNO stands at 3.8B. In comparison, ADMA has a market cap of 4.1B. Regarding current trading prices, SLNO is priced at $77.36, while ADMA trades at $16.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLNO currently has a P/E ratio of -16.97, whereas ADMA's P/E ratio is 19.99. In terms of profitability, SLNO's ROE is -0.74%, compared to ADMA's ROE of +0.62%. Regarding short-term risk, SLNO is more volatile compared to ADMA. This indicates potentially higher risk in terms of short-term price fluctuations for SLNO.Check ADMA's competition here
SLNO vs AKRO Comparison August 2025
SLNO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLNO stands at 3.8B. In comparison, AKRO has a market cap of 3.9B. Regarding current trading prices, SLNO is priced at $77.36, while AKRO trades at $50.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLNO currently has a P/E ratio of -16.97, whereas AKRO's P/E ratio is -12.96. In terms of profitability, SLNO's ROE is -0.74%, compared to AKRO's ROE of -0.32%. Regarding short-term risk, SLNO is less volatile compared to AKRO. This indicates potentially lower risk in terms of short-term price fluctuations for SLNO.Check AKRO's competition here
SLNO vs ZLAB Comparison August 2025
SLNO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLNO stands at 3.8B. In comparison, ZLAB has a market cap of 3.9B. Regarding current trading prices, SLNO is priced at $77.36, while ZLAB trades at $34.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLNO currently has a P/E ratio of -16.97, whereas ZLAB's P/E ratio is -17.86. In terms of profitability, SLNO's ROE is -0.74%, compared to ZLAB's ROE of -0.27%. Regarding short-term risk, SLNO is more volatile compared to ZLAB. This indicates potentially higher risk in terms of short-term price fluctuations for SLNO.Check ZLAB's competition here
SLNO vs TLX Comparison August 2025
SLNO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLNO stands at 3.8B. In comparison, TLX has a market cap of 3.9B. Regarding current trading prices, SLNO is priced at $77.36, while TLX trades at $10.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLNO currently has a P/E ratio of -16.97, whereas TLX's P/E ratio is 128.22. In terms of profitability, SLNO's ROE is -0.74%, compared to TLX's ROE of +0.10%. Regarding short-term risk, SLNO is more volatile compared to TLX. This indicates potentially higher risk in terms of short-term price fluctuations for SLNO.Check TLX's competition here
SLNO vs PTCT Comparison August 2025
SLNO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLNO stands at 3.8B. In comparison, PTCT has a market cap of 3.9B. Regarding current trading prices, SLNO is priced at $77.36, while PTCT trades at $48.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLNO currently has a P/E ratio of -16.97, whereas PTCT's P/E ratio is 6.92. In terms of profitability, SLNO's ROE is -0.74%, compared to PTCT's ROE of -0.99%. Regarding short-term risk, SLNO is more volatile compared to PTCT. This indicates potentially higher risk in terms of short-term price fluctuations for SLNO.Check PTCT's competition here
SLNO vs RYZB Comparison August 2025
SLNO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLNO stands at 3.8B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, SLNO is priced at $77.36, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLNO currently has a P/E ratio of -16.97, whereas RYZB's P/E ratio is -57.86. In terms of profitability, SLNO's ROE is -0.74%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, SLNO is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for SLNO.Check RYZB's competition here
SLNO vs CBAY Comparison August 2025
SLNO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLNO stands at 3.8B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, SLNO is priced at $77.36, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLNO currently has a P/E ratio of -16.97, whereas CBAY's P/E ratio is -32.81. In terms of profitability, SLNO's ROE is -0.74%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, SLNO is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for SLNO.Check CBAY's competition here
SLNO vs SWTX Comparison August 2025
SLNO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLNO stands at 3.8B. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, SLNO is priced at $77.36, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLNO currently has a P/E ratio of -16.97, whereas SWTX's P/E ratio is -13.78. In terms of profitability, SLNO's ROE is -0.74%, compared to SWTX's ROE of -0.51%. Regarding short-term risk, SLNO is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for SLNO.Check SWTX's competition here
SLNO vs APLS Comparison August 2025
SLNO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLNO stands at 3.8B. In comparison, APLS has a market cap of 3.5B. Regarding current trading prices, SLNO is priced at $77.36, while APLS trades at $27.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLNO currently has a P/E ratio of -16.97, whereas APLS's P/E ratio is -15.16. In terms of profitability, SLNO's ROE is -0.74%, compared to APLS's ROE of -1.16%. Regarding short-term risk, SLNO is less volatile compared to APLS. This indicates potentially lower risk in terms of short-term price fluctuations for SLNO.Check APLS's competition here
SLNO vs PTGX Comparison August 2025
SLNO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLNO stands at 3.8B. In comparison, PTGX has a market cap of 3.5B. Regarding current trading prices, SLNO is priced at $77.36, while PTGX trades at $54.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLNO currently has a P/E ratio of -16.97, whereas PTGX's P/E ratio is 76.81. In terms of profitability, SLNO's ROE is -0.74%, compared to PTGX's ROE of +0.08%. Regarding short-term risk, SLNO is more volatile compared to PTGX. This indicates potentially higher risk in terms of short-term price fluctuations for SLNO.Check PTGX's competition here
SLNO vs MLTX Comparison August 2025
SLNO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLNO stands at 3.8B. In comparison, MLTX has a market cap of 3.5B. Regarding current trading prices, SLNO is priced at $77.36, while MLTX trades at $54.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLNO currently has a P/E ratio of -16.97, whereas MLTX's P/E ratio is -19.49. In terms of profitability, SLNO's ROE is -0.74%, compared to MLTX's ROE of -0.42%. Regarding short-term risk, SLNO is more volatile compared to MLTX. This indicates potentially higher risk in terms of short-term price fluctuations for SLNO.Check MLTX's competition here
SLNO vs LEGN Comparison August 2025
SLNO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLNO stands at 3.8B. In comparison, LEGN has a market cap of 3.4B. Regarding current trading prices, SLNO is priced at $77.36, while LEGN trades at $37.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLNO currently has a P/E ratio of -16.97, whereas LEGN's P/E ratio is -21.07. In terms of profitability, SLNO's ROE is -0.74%, compared to LEGN's ROE of -0.31%. Regarding short-term risk, SLNO is more volatile compared to LEGN. This indicates potentially higher risk in terms of short-term price fluctuations for SLNO.Check LEGN's competition here
SLNO vs MIRM Comparison August 2025
SLNO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLNO stands at 3.8B. In comparison, MIRM has a market cap of 3.4B. Regarding current trading prices, SLNO is priced at $77.36, while MIRM trades at $64.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLNO currently has a P/E ratio of -16.97, whereas MIRM's P/E ratio is -56.14. In terms of profitability, SLNO's ROE is -0.74%, compared to MIRM's ROE of -0.25%. Regarding short-term risk, SLNO is more volatile compared to MIRM. This indicates potentially higher risk in terms of short-term price fluctuations for SLNO.Check MIRM's competition here
SLNO vs MTSR Comparison August 2025
SLNO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLNO stands at 3.8B. In comparison, MTSR has a market cap of 3.3B. Regarding current trading prices, SLNO is priced at $77.36, while MTSR trades at $30.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLNO currently has a P/E ratio of -16.97, whereas MTSR's P/E ratio is -10.59. In terms of profitability, SLNO's ROE is -0.74%, compared to MTSR's ROE of -0.90%. Regarding short-term risk, SLNO is less volatile compared to MTSR. This indicates potentially lower risk in terms of short-term price fluctuations for SLNO.Check MTSR's competition here
SLNO vs KYMR Comparison August 2025
SLNO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLNO stands at 3.8B. In comparison, KYMR has a market cap of 3B. Regarding current trading prices, SLNO is priced at $77.36, while KYMR trades at $41.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLNO currently has a P/E ratio of -16.97, whereas KYMR's P/E ratio is -12.21. In terms of profitability, SLNO's ROE is -0.74%, compared to KYMR's ROE of -0.32%. Regarding short-term risk, SLNO is more volatile compared to KYMR. This indicates potentially higher risk in terms of short-term price fluctuations for SLNO.Check KYMR's competition here
SLNO vs SRRK Comparison August 2025
SLNO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLNO stands at 3.8B. In comparison, SRRK has a market cap of 3B. Regarding current trading prices, SLNO is priced at $77.36, while SRRK trades at $32.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLNO currently has a P/E ratio of -16.97, whereas SRRK's P/E ratio is -10.76. In terms of profitability, SLNO's ROE is -0.74%, compared to SRRK's ROE of -1.27%. Regarding short-term risk, SLNO is more volatile compared to SRRK. This indicates potentially higher risk in terms of short-term price fluctuations for SLNO.Check SRRK's competition here
SLNO vs LGND Comparison August 2025
SLNO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLNO stands at 3.8B. In comparison, LGND has a market cap of 3B. Regarding current trading prices, SLNO is priced at $77.36, while LGND trades at $153.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLNO currently has a P/E ratio of -16.97, whereas LGND's P/E ratio is -37.40. In terms of profitability, SLNO's ROE is -0.74%, compared to LGND's ROE of -0.09%. Regarding short-term risk, SLNO is more volatile compared to LGND. This indicates potentially higher risk in terms of short-term price fluctuations for SLNO.Check LGND's competition here
SLNO vs XENE Comparison August 2025
SLNO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLNO stands at 3.8B. In comparison, XENE has a market cap of 2.9B. Regarding current trading prices, SLNO is priced at $77.36, while XENE trades at $37.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLNO currently has a P/E ratio of -16.97, whereas XENE's P/E ratio is -10.77. In terms of profitability, SLNO's ROE is -0.74%, compared to XENE's ROE of -0.32%. Regarding short-term risk, SLNO is more volatile compared to XENE. This indicates potentially higher risk in terms of short-term price fluctuations for SLNO.Check XENE's competition here
SLNO vs CRNX Comparison August 2025
SLNO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLNO stands at 3.8B. In comparison, CRNX has a market cap of 2.9B. Regarding current trading prices, SLNO is priced at $77.36, while CRNX trades at $29.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLNO currently has a P/E ratio of -16.97, whereas CRNX's P/E ratio is -7.49. In terms of profitability, SLNO's ROE is -0.74%, compared to CRNX's ROE of -0.32%. Regarding short-term risk, SLNO is more volatile compared to CRNX. This indicates potentially higher risk in terms of short-term price fluctuations for SLNO.Check CRNX's competition here
SLNO vs MORF Comparison August 2025
SLNO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLNO stands at 3.8B. In comparison, MORF has a market cap of 2.9B. Regarding current trading prices, SLNO is priced at $77.36, while MORF trades at $56.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLNO currently has a P/E ratio of -16.97, whereas MORF's P/E ratio is -14.88. In terms of profitability, SLNO's ROE is -0.74%, compared to MORF's ROE of -0.16%. Regarding short-term risk, SLNO is more volatile compared to MORF. This indicates potentially higher risk in terms of short-term price fluctuations for SLNO.Check MORF's competition here
SLNO vs RARE Comparison August 2025
SLNO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLNO stands at 3.8B. In comparison, RARE has a market cap of 2.9B. Regarding current trading prices, SLNO is priced at $77.36, while RARE trades at $29.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLNO currently has a P/E ratio of -16.97, whereas RARE's P/E ratio is -5.42. In terms of profitability, SLNO's ROE is -0.74%, compared to RARE's ROE of -2.37%. Regarding short-term risk, SLNO is more volatile compared to RARE. This indicates potentially higher risk in terms of short-term price fluctuations for SLNO.Check RARE's competition here
SLNO vs MOR Comparison August 2025
SLNO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLNO stands at 3.8B. In comparison, MOR has a market cap of 2.9B. Regarding current trading prices, SLNO is priced at $77.36, while MOR trades at $18.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLNO currently has a P/E ratio of -16.97, whereas MOR's P/E ratio is -12.64. In terms of profitability, SLNO's ROE is -0.74%, compared to MOR's ROE of -1.84%. Regarding short-term risk, SLNO is more volatile compared to MOR. This indicates potentially higher risk in terms of short-term price fluctuations for SLNO.Check MOR's competition here
SLNO vs ARWR Comparison August 2025
SLNO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLNO stands at 3.8B. In comparison, ARWR has a market cap of 2.8B. Regarding current trading prices, SLNO is priced at $77.36, while ARWR trades at $18.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLNO currently has a P/E ratio of -16.97, whereas ARWR's P/E ratio is -17.09. In terms of profitability, SLNO's ROE is -0.74%, compared to ARWR's ROE of -0.41%. Regarding short-term risk, SLNO is more volatile compared to ARWR. This indicates potentially higher risk in terms of short-term price fluctuations for SLNO.Check ARWR's competition here
SLNO vs NAMS Comparison August 2025
SLNO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLNO stands at 3.8B. In comparison, NAMS has a market cap of 2.8B. Regarding current trading prices, SLNO is priced at $77.36, while NAMS trades at $25.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLNO currently has a P/E ratio of -16.97, whereas NAMS's P/E ratio is -15.77. In terms of profitability, SLNO's ROE is -0.74%, compared to NAMS's ROE of -0.25%. Regarding short-term risk, SLNO is more volatile compared to NAMS. This indicates potentially higher risk in terms of short-term price fluctuations for SLNO.Check NAMS's competition here
SLNO vs KDNY Comparison August 2025
SLNO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLNO stands at 3.8B. In comparison, KDNY has a market cap of 2.7B. Regarding current trading prices, SLNO is priced at $77.36, while KDNY trades at $40.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLNO currently has a P/E ratio of -16.97, whereas KDNY's P/E ratio is -12.47. In terms of profitability, SLNO's ROE is -0.74%, compared to KDNY's ROE of -0.41%. Regarding short-term risk, SLNO is more volatile compared to KDNY. This indicates potentially higher risk in terms of short-term price fluctuations for SLNO.Check KDNY's competition here
SLNO vs IMVT Comparison August 2025
SLNO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLNO stands at 3.8B. In comparison, IMVT has a market cap of 2.7B. Regarding current trading prices, SLNO is priced at $77.36, while IMVT trades at $15.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLNO currently has a P/E ratio of -16.97, whereas IMVT's P/E ratio is -5.36. In terms of profitability, SLNO's ROE is -0.74%, compared to IMVT's ROE of -0.84%. Regarding short-term risk, SLNO is more volatile compared to IMVT. This indicates potentially higher risk in terms of short-term price fluctuations for SLNO.Check IMVT's competition here
SLNO vs MYOV Comparison August 2025
SLNO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLNO stands at 3.8B. In comparison, MYOV has a market cap of 2.6B. Regarding current trading prices, SLNO is priced at $77.36, while MYOV trades at $26.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLNO currently has a P/E ratio of -16.97, whereas MYOV's P/E ratio is -14.05. In terms of profitability, SLNO's ROE is -0.74%, compared to MYOV's ROE of +0.50%. Regarding short-term risk, SLNO is more volatile compared to MYOV. This indicates potentially higher risk in terms of short-term price fluctuations for SLNO.Check MYOV's competition here
SLNO vs CPRX Comparison August 2025
SLNO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLNO stands at 3.8B. In comparison, CPRX has a market cap of 2.5B. Regarding current trading prices, SLNO is priced at $77.36, while CPRX trades at $20.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLNO currently has a P/E ratio of -16.97, whereas CPRX's P/E ratio is 12.26. In terms of profitability, SLNO's ROE is -0.74%, compared to CPRX's ROE of +0.27%. Regarding short-term risk, SLNO is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for SLNO.Check CPRX's competition here
SLNO vs KNSA Comparison August 2025
SLNO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLNO stands at 3.8B. In comparison, KNSA has a market cap of 2.5B. Regarding current trading prices, SLNO is priced at $77.36, while KNSA trades at $33.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLNO currently has a P/E ratio of -16.97, whereas KNSA's P/E ratio is 667.60. In terms of profitability, SLNO's ROE is -0.74%, compared to KNSA's ROE of +0.01%. Regarding short-term risk, SLNO is more volatile compared to KNSA. This indicates potentially higher risk in terms of short-term price fluctuations for SLNO.Check KNSA's competition here
SLNO vs RXRX Comparison August 2025
SLNO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLNO stands at 3.8B. In comparison, RXRX has a market cap of 2.5B. Regarding current trading prices, SLNO is priced at $77.36, while RXRX trades at $5.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLNO currently has a P/E ratio of -16.97, whereas RXRX's P/E ratio is -3.19. In terms of profitability, SLNO's ROE is -0.74%, compared to RXRX's ROE of -0.76%. Regarding short-term risk, SLNO is more volatile compared to RXRX. This indicates potentially higher risk in terms of short-term price fluctuations for SLNO.Check RXRX's competition here
SLNO vs CNTA Comparison August 2025
SLNO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLNO stands at 3.8B. In comparison, CNTA has a market cap of 2.4B. Regarding current trading prices, SLNO is priced at $77.36, while CNTA trades at $17.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLNO currently has a P/E ratio of -16.97, whereas CNTA's P/E ratio is -9.76. In terms of profitability, SLNO's ROE is -0.74%, compared to CNTA's ROE of -0.57%. Regarding short-term risk, SLNO is less volatile compared to CNTA. This indicates potentially lower risk in terms of short-term price fluctuations for SLNO.Check CNTA's competition here
SLNO vs IBRX Comparison August 2025
SLNO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLNO stands at 3.8B. In comparison, IBRX has a market cap of 2.4B. Regarding current trading prices, SLNO is priced at $77.36, while IBRX trades at $2.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLNO currently has a P/E ratio of -16.97, whereas IBRX's P/E ratio is -5.31. In terms of profitability, SLNO's ROE is -0.74%, compared to IBRX's ROE of +0.61%. Regarding short-term risk, SLNO is less volatile compared to IBRX. This indicates potentially lower risk in terms of short-term price fluctuations for SLNO.Check IBRX's competition here
SLNO vs VCYT Comparison August 2025
SLNO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLNO stands at 3.8B. In comparison, VCYT has a market cap of 2.4B. Regarding current trading prices, SLNO is priced at $77.36, while VCYT trades at $30.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLNO currently has a P/E ratio of -16.97, whereas VCYT's P/E ratio is 88.88. In terms of profitability, SLNO's ROE is -0.74%, compared to VCYT's ROE of +0.02%. Regarding short-term risk, SLNO is more volatile compared to VCYT. This indicates potentially higher risk in terms of short-term price fluctuations for SLNO.Check VCYT's competition here
SLNO vs PRVB Comparison August 2025
SLNO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLNO stands at 3.8B. In comparison, PRVB has a market cap of 2.4B. Regarding current trading prices, SLNO is priced at $77.36, while PRVB trades at $24.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLNO currently has a P/E ratio of -16.97, whereas PRVB's P/E ratio is -16.43. In terms of profitability, SLNO's ROE is -0.74%, compared to PRVB's ROE of +1.33%. Regarding short-term risk, SLNO is more volatile compared to PRVB. This indicates potentially higher risk in terms of short-term price fluctuations for SLNO.Check PRVB's competition here
SLNO vs LBPH Comparison August 2025
SLNO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLNO stands at 3.8B. In comparison, LBPH has a market cap of 2.3B. Regarding current trading prices, SLNO is priced at $77.36, while LBPH trades at $59.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLNO currently has a P/E ratio of -16.97, whereas LBPH's P/E ratio is -26.66. In terms of profitability, SLNO's ROE is -0.74%, compared to LBPH's ROE of -0.21%. Regarding short-term risk, SLNO is more volatile compared to LBPH. This indicates potentially higher risk in terms of short-term price fluctuations for SLNO.Check LBPH's competition here
SLNO vs TARS Comparison August 2025
SLNO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLNO stands at 3.8B. In comparison, TARS has a market cap of 2.3B. Regarding current trading prices, SLNO is priced at $77.36, while TARS trades at $54.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLNO currently has a P/E ratio of -16.97, whereas TARS's P/E ratio is -23.67. In terms of profitability, SLNO's ROE is -0.74%, compared to TARS's ROE of -0.32%. Regarding short-term risk, SLNO is more volatile compared to TARS. This indicates potentially higher risk in terms of short-term price fluctuations for SLNO.Check TARS's competition here
SLNO vs FOLD Comparison August 2025
SLNO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLNO stands at 3.8B. In comparison, FOLD has a market cap of 2.3B. Regarding current trading prices, SLNO is priced at $77.36, while FOLD trades at $7.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLNO currently has a P/E ratio of -16.97, whereas FOLD's P/E ratio is -61.67. In terms of profitability, SLNO's ROE is -0.74%, compared to FOLD's ROE of -0.20%. Regarding short-term risk, SLNO is more volatile compared to FOLD. This indicates potentially higher risk in terms of short-term price fluctuations for SLNO.Check FOLD's competition here
SLNO vs DICE Comparison August 2025
SLNO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLNO stands at 3.8B. In comparison, DICE has a market cap of 2.3B. Regarding current trading prices, SLNO is priced at $77.36, while DICE trades at $47.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLNO currently has a P/E ratio of -16.97, whereas DICE's P/E ratio is -21.91. In terms of profitability, SLNO's ROE is -0.74%, compared to DICE's ROE of +0.56%. Regarding short-term risk, SLNO is more volatile compared to DICE. This indicates potentially higher risk in terms of short-term price fluctuations for SLNO.Check DICE's competition here
SLNO vs LQDA Comparison August 2025
SLNO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLNO stands at 3.8B. In comparison, LQDA has a market cap of 2.2B. Regarding current trading prices, SLNO is priced at $77.36, while LQDA trades at $26.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLNO currently has a P/E ratio of -16.97, whereas LQDA's P/E ratio is -14.26. In terms of profitability, SLNO's ROE is -0.74%, compared to LQDA's ROE of -1.58%. Regarding short-term risk, SLNO is less volatile compared to LQDA. This indicates potentially lower risk in terms of short-term price fluctuations for SLNO.Check LQDA's competition here
SLNO vs APGE Comparison August 2025
SLNO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLNO stands at 3.8B. In comparison, APGE has a market cap of 2.2B. Regarding current trading prices, SLNO is priced at $77.36, while APGE trades at $38.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLNO currently has a P/E ratio of -16.97, whereas APGE's P/E ratio is -9.01. In terms of profitability, SLNO's ROE is -0.74%, compared to APGE's ROE of -0.23%. Regarding short-term risk, SLNO is more volatile compared to APGE. This indicates potentially higher risk in terms of short-term price fluctuations for SLNO.Check APGE's competition here
SLNO vs OCUL Comparison August 2025
SLNO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLNO stands at 3.8B. In comparison, OCUL has a market cap of 2.2B. Regarding current trading prices, SLNO is priced at $77.36, while OCUL trades at $12.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLNO currently has a P/E ratio of -16.97, whereas OCUL's P/E ratio is -10.02. In terms of profitability, SLNO's ROE is -0.74%, compared to OCUL's ROE of -0.70%. Regarding short-term risk, SLNO is more volatile compared to OCUL. This indicates potentially higher risk in terms of short-term price fluctuations for SLNO.Check OCUL's competition here
SLNO vs BLTE Comparison August 2025
SLNO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLNO stands at 3.8B. In comparison, BLTE has a market cap of 2.2B. Regarding current trading prices, SLNO is priced at $77.36, while BLTE trades at $68.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLNO currently has a P/E ratio of -16.97, whereas BLTE's P/E ratio is -42.99. In terms of profitability, SLNO's ROE is -0.74%, compared to BLTE's ROE of -0.37%. Regarding short-term risk, SLNO is more volatile compared to BLTE. This indicates potentially higher risk in terms of short-term price fluctuations for SLNO.Check BLTE's competition here
SLNO vs AGIO Comparison August 2025
SLNO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLNO stands at 3.8B. In comparison, AGIO has a market cap of 2.2B. Regarding current trading prices, SLNO is priced at $77.36, while AGIO trades at $36.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLNO currently has a P/E ratio of -16.97, whereas AGIO's P/E ratio is 3.28. In terms of profitability, SLNO's ROE is -0.74%, compared to AGIO's ROE of +0.43%. Regarding short-term risk, SLNO is more volatile compared to AGIO. This indicates potentially higher risk in terms of short-term price fluctuations for SLNO.Check AGIO's competition here
SLNO vs DNLI Comparison August 2025
SLNO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SLNO stands at 3.8B. In comparison, DNLI has a market cap of 2.1B. Regarding current trading prices, SLNO is priced at $77.36, while DNLI trades at $14.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SLNO currently has a P/E ratio of -16.97, whereas DNLI's P/E ratio is -5.23. In terms of profitability, SLNO's ROE is -0.74%, compared to DNLI's ROE of -0.41%. Regarding short-term risk, SLNO is more volatile compared to DNLI. This indicates potentially higher risk in terms of short-term price fluctuations for SLNO.Check DNLI's competition here